Showing results (91-100 of 126) with videos related to

Sort By:
Pageof 13
Haematologica|January 19, 2019
Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosisMarie Robin, Sylvie Chevret, Linda Koster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2021
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic SyndromesDavid A Sallman, Amy E DeZern, Guillermo Garcia-Manero, et al.
Blood Advances|October 25, 2024
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OSThomas Cluzeau, Fabio Guolo, Edmond Chiche, et al.
Blood|August 19, 2021
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapyRaphael Itzykson, Elise Fournier, Céline Berthon, et al.
Blood Advances|November 19, 2019
Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysisKathy L McGraw, Chia-Ho Cheng, Y Ann Chen, et al.
American Journal of Hematology|December 31, 2013
Azacitidine in untreated acute myeloid leukemia: a report on 149 patientsSylvain Thépot, Raphael Itzykson, Valerie Seegers, et al.
British Journal of Haematology|April 19, 2022
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutationsLionel Adès, Nicolas Duployez, Agnes Guerci-Bresler, et al.
American Journal of Hematology|February 6, 2024
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemiaElias Jabbour, Gerhard Zugmaier, Vaibhav Agrawal, et al.
Lancet (London, England)|June 13, 2023
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trialUwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, et al.
Blood Advances|December 8, 2022
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AMLStéphane de Botton, Thomas Cluzeau, Carlos Vigil, et al.
Pageof 13